TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: In a phase 1 trial, patients with newly diagnosed CD30-expressing PTCL who received BV combined with CHOP or CHOP without vincristine (CHP) achieved an estimated 5-year progression-free survival (PFS) rate of 52%, and an estimated overall survival (OS) rate of 80% [9, 10].